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Therapeutic drug monitoring (TDM)
A B S T R A C T
Purpose: Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) in serum is frequently used in
clinical settings however saliva could be an alternative to measure free concentration of drugs. In the
present study, we observed the possible correlation of VPA concentration between serum and saliva in
persons with epilepsy (PWE).
Methods: A total of 59 paired serum and saliva samples were assayed from 65 consecutive PWE
(51 males and 14 females; age range 9–65 years). Patients were subjected to either VPA monotherapy or
its combination with other AEDs for at least three months. Steady state trough concentration of unbound
VPA drug was quantiﬁed using HPLC. The correlation between serum and saliva free VPA concentration
was evaluated.
Results: Out of 65 patients, 27 were on monotherapy of VPA and 38 were on VPA with other antiepileptic
drugs. Saliva VPA concentration signiﬁcantly correlated with serum free VPA concentration (p < 0.05).
Poor correlation was observed between serum and saliva VPA concentration with the daily dose
(p > 0.05) respectively.
Conclusions: Our study reveals that serum and saliva VPA concentrations are signiﬁcantly associated in
PWE. These associations may facilitate monitoring and evaluation of VPA levels non-invasively for PWE.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproic acid (2-propyl pentanoic acid, VPA) is a broad spectrum
AED and is frequently prescribed by physicians to control various
forms of seizures and syndromes. It is also indicated for the treatment
of diseases like schizophrenia, bipolar disorder,  depression, neuro-
pathic pain and prophylactic treatment of migraine.1TDM of VPA plays
an important role in understanding its efﬁcacy as well as toxicity. As
clinical effects of therapy are more closely related to the levels of drug
than dose, TDM may be helpful to optimize the dose in order to have
enhanced efﬁcacy and to minimize toxicity.2,3 In TDM, blood samples
are commonly used for monitoring the concentrations of various
AEDs in a routine practice. As of now, there in evidence supporting
saliva being used as an alternative to serum for monitoring the free
concentration of AEDs and few studies have shown a signiﬁcant asso-
ciation between serum and saliva concentration in PWE.3,4 In different
clinical settings, several pharmacokinetic and pharmacodynamic* Corresponding author. Tel.: +91 011 26594494; fax: +91 011 2658848.
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for the VPA levels in both serum and saliva. However these
associations were affected by either variability of pH, interpatient
variability, precision of different assays, drug–drug interactions or
genetic variations in diverse ethnic population.2,3,8 In some reports, it
has been shown that a signiﬁcant correlation of saliva levels with
serum levels of VPA is there using different approaches,5,7 whereas
others have observed no association.6,8,9 These inconsistent reports
give an opportunity to investigate this aspect in other populations. In
the Indian population, serum samples for VPA estimation were
observed however to the best of our knowledge this is a ﬁrst report in
Indian ethnicity where we used saliva for VPA estimation in PWE. We
studied the association of free VPA concentrations to ascertain the
correlation between serum and saliva in PWE.
2. Materials and methods
2.1. Ethical approval and study subjects
All PWE were prospectively recruited from 2010 to 2012 at the
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Fig. 1. Comparative graphical presentation for mono-, duo- and poly-therapy of
PWE with VPA level in serum and saliva.
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was approved by Institute Ethics Committee and written informed
consent was obtained from all subjects or guardians prior to
sample collection. PWE, who were taking either VPA alone or in
combination with other AEDs for a minimum of 3 months; able to
produce saliva and age 65 years were included in our study. PWE
who were either unable to give consent or had history of illness like
stroke, tuberculosis, diabetes, endocrinal disorders, AIDS etc. or
had adverse effect of AEDs were excluded. Diagnosis of epilepsy
was made according to International League Against Epilepsy
(ILAE) guidelines; 2010. Clinical and demographic details were
recorded during recruitment.
2.2. Sample collection and determination of free VPA concentration by
HPLC
Venous blood samples (3 mL) were collected at trough level
(just before the next dose) in plain vials (BD Vaccutainer tube, BD
Bioscience, USA), at the same time, saliva samples were also
collected by placing commercially available salivette cotton
swab with citric acid (Sarstedt, Nu¨mbrecht, Germany). Blood and
saliva samples were centrifuged within 2 h at 3000 rpm for
10 min at 4 8C. Clear supernatant of serum and saliva fractions
were stored at 80 8C until further analysis. The free concentra-
tion of VPA in serum and saliva was quantiﬁed by HPLC System
(Agilent 1200 series, Agilent Technologies, USA) using Chromo-
lith RP, 18e (100 mm  4.6 mm) packed column (Merck,
Germany). Further analysis was carried out as described method
by Kishore et al.10 with slightl alterations (ﬂow rate 1 mL/min,
injection volume 25 mL, column oven temperature 35 8C, run
time 10 min and wave length 210 nm). The standard curve of VPA
for saliva and serum was plotted in the different concentrations
range (5–100 mg/mL). Less than 5% intra and inter day variability
for VPA was observed.
2.3. Statistical analysis
All data were analyzed using STATA [v. 11.0 (Statacorp, College
Station, TX, USA)] and summarized as mean  SD. The Pearson
correlation coefﬁcient was used when data had a normal distribu-
tion. Otherwise, the spearman rank-correlation coefﬁcient was
performed to elucidate the correlation between serum and saliva
VPA concentration. The p < 0.05 was considered as statistically
signiﬁcant.
3. Results
3.1. Demographic and clinical details
A total of 65 PWE were recruited with the age range between
9 and 62 years (22.70  9.96, mean  SD) and their body weight
ranged 26.0–98.4 kg (53.55  12.92, mean  SD). The percentage
of male (78.5%) was higher than female (21.5%). The mean  SD
for duration of epilepsy, age at onset of seizures, frequency of
seizures is presented in (years) and duration of treatment in
(months) were 7.68  6.93, 15.09  9.92, 76.12  260.47 and
52.92  56.01 respectively. Patients with generalized seizures
(61.5%) were higher as compared to focal seizures (38.5%) and
seizures control was achieved in 18 (27.7%) patients with one or two
AEDs regimen whereas 47 (72.3%) patients had drug refractory
epilepsy (DRE) with more than two drugs. Out of 65 PWE, higher
percentage of patients (58.5%) were taking VPA in combination with
other AEDs, i.e. phenytoin, carbamazepine, phenobarbital, levetir-
acetam, lamotrigine and clobazam etc. at a daily dose of
(996.05  418.23 mg/day mean  SD) as compared to VPA (41.5%)
alone (807.40  281.37 mg/day mean  SD). Drug doses were adjustedwith their body weight (53.55  12.92 kg; range, 26.0–98.4 kg). In
65 patients, 41.5% of PWE were on monotherapy, 40% of PWE on duo-
therapy whereas 18% of PWE on polytherapy.  As shown in Fig. 1, the
levels of VPA in mono-, and poly-therapy were not found statistically
signiﬁcant (p > 0.05) in free serum and saliva whereas in duo-
therapy PWE it showed a statistically signiﬁcant association
(p < 0.05). Implying that the interaction of two AEDs may alter
the level of drugs in PWE. Interestingly, with increase in the number
of drugs in poly-therapy increased, it remains unchanged as in
monotherapy.
3.2. Correlation between saliva and serum unbound VPA
concentration
Out of 65 PWE, paired samples (saliva and serum) were
analyzed in 59 subjects. The VPA levels of serum in 6 patients
were below the limit of quantiﬁcation. However, mean  SD
(11.5  8.5 mg/mL) of VPA levels of saliva in these subjects were
observed. These patients were excluded for correlation analysis.
The mean  SD of VPA concentration in free serum and saliva were
47.35  39.02 mg/mL and 19.02  19.43 mg/mL respectively. The
mean ratio of saliva to serum free concentration of VPA was
0.68  1.29%. Free serum VPA concentrations signiﬁcantly corre-
lated with that of Saliva VPA concentrations (r = 36; p < 0.004)
while determination of correlation coefﬁcient (r2), slope, and
conﬁdence interval (CI) were 0.13, 0.73 and 0.23–1.22 respectively.
As shown in Fig. 2A, we observed a linear relationship between the
saliva and serum free concentration of VPA. However, poor
correlation coefﬁcient was observed between serum and saliva
VPA concentration with daily dose (r2 = 0.01 and r2 = 0.02)
respectively (Fig. 2B – left and right). These associations were
not statistically signiﬁcant (p > 0.05) and showed non-linear
relation in PWE. As expected, we found that drug dose signiﬁcantly
correlated with age and weight (r = 0.39 and p < 0.005),
(r = 0.40 and p < 0.0001).
4. Discussion
TDM is highly useful in determination of drug levels and
identiﬁcation of therapeutic failure either due to under or
optimal dose or toxicity due to an inter individual variability.
Monitoring of VPA using saliva as compared to serum is an
essential approach for the determination of free drug concentra-
tions.4 Through simple diffusion, free drug transports across the
biological membrane and reaches the effector site according to
the concentration gradient.2,3 In our study by comparing the VPA
estimation in saliva and serum, we observed that 64.3% of
Fig. 2. A. Scatter plot for the correlation between serum and saliva free valproic acid in 65 persons with epilepsy (PWE). B. Scatter plot for the correlation between daily dose of
VPA with serum and saliva concentration in 65 persons with epilepsy (PWE) (left and right respectively).
R. Dwivedi et al. / Seizure 25 (2015) 187–190 189patients in sub therapeutic range had seizure control and this
was similar to results in an Iranian population.11 Interestingly,
we found a poor association between VPA dose and its
concentration in serum and saliva because of rapid or slow
metabolization of drug and a heterogeneous population, this is
similar to previous published reports in a pediatric population.12
The mean ratio of saliva to serum free VPA concentration
indicates that the saliva levels can predict the free drug
concentrations in serum and it also shows the protein binding
of VPA in both. In our study, A statistically signiﬁcant (p < 0.004)
correlation was found in serum free VPA with saliva VPA
concentration in an Indian population. Using different analytical
approaches with different populations, the saliva VPA levels had
signiﬁcant correlation with total and free level of VPA in the
serum.5,7,13 In contrast, other studies have reported a weak
correlation which was not signiﬁcant.6,8,9 Our results indicate
that saliva could be used as a good substitute for the monitoring
of free VPA concentration because it correlated with the free drug
concentrations in serum. The limitation of our study was that our
population was heterogeneous, affected by either the variability
of pH, genetic variability and dug drug interaction in duo- or
polytherapy. This may result in either a weak or strong
association with substantial variation that alters the correlation
coefﬁcient. In addition, it also limits that the analysis of free VPA
(serum or saliva) requires specialized laboratory techniques (e.g.,
ultraﬁltration followed by HPLC or LC/MS) that may not be
available in many hospital laboratories in resource limited
settings. Therefore, it necessitates referral and extra expenses to
perform analysis in an equipped external reference laboratory. In
conclusion, our results suggest a positive correlation and help
understand TDM system in our population. Saliva could be an
alternative and non-invasive method of sampling in TDM. The
collection of saliva is painless, convenient, easy to process, less
stressful and does not involve any risk of secondary infection or
thrombosis as that of blood.Conﬂict of interest
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